Trial Profile
Study of dapagliflozin on liver dysfunction, hepatic steatosis, and serum levels of sDPP-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 27 Feb 2019 Results assessing the impact of dapagliflozin on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease, published in the International Journal of Clinical Practice
- 18 Oct 2018 New trial record